Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
|Articles|July 1, 2000
The American Journal of Managed Care
- July 2000
- Volume 6
- Issue 7
Comparing the Medical Expenses of Children with Medicaid and Commercial Insurance in an HMO
Advertisement
Articles in this issue
over 26 years ago
Improving the Sensitivity of Cervical Cytology: What Are the Issues?over 26 years ago
Why Are Drug Prices Lower in Canada?over 26 years ago
Design and Implementation of an Inpatient Disease Management ProgramAdvertisement
Related to this article
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
HS Comorbidities: Navigating Metabolic, Bowel, Cardiovascular, and Mental Health Risks
5